TY - JOUR
T1 - Seroprevalence of sars-cov-2 among blood donors and changes after introduction of public health and social measures, london, uk
AU - Amirthalingam, Gayatri
AU - Whitaker, Heather
AU - Brooks, Timothy
AU - Brown, Kevin
AU - Hoschler, Katja
AU - Linley, Ezra
AU - Borrow, Raymond
AU - Brown, Colin
AU - Watkins, Nick
AU - Roberts, David J.
AU - Solomon, Danielle
AU - Gower, Charlotte
AU - Le Polain De Waroux, Olivier
AU - Andrews, Nicholas
AU - Ramsay, Mary E.
N1 - Publisher Copyright:
© 2021 Centers for Disease Control and Prevention (CDC). All rights reserved.
PY - 2021/7
Y1 - 2021/7
N2 - We describe results of testing blood donors in London, UK, for severe acute respiratory disease coronavirus 2 (SARS-CoV-2) IgG before and after lockdown measures. Anonymized samples from donors 17-69 years of age were tested using 3 assays: Euroimmun IgG, Abbott IgG, and an immunoglobulin receptor-binding domain assay developed by Public Health England. Seroprevalence increased from 3.0% prelockdown (week 13, beginning March 23, 2020) to 10.4% during lockdown (weeks 15- 16) and 12.3% postlockdown (week 18) by the Abbott assay. Estimates were 2.9% prelockdown, 9.9% during lockdown, and 13.0% postlockdown by the Euroimmun assay and 3.5% prelockdown, 11.8% during lockdown, and 14.1% postlockdown by the receptor-binding domain assay. By early May 2020, nearly 1 in 7 donors had evidence of past SARS-CoV-2 infection. Combining results from the Abbott and Euroimmun assays increased seroprevalence by 1.6%, 2.3%, and 0.6% at the 3 timepoints compared with Euroimmun alone, demonstrating the value of using multiple assays.
AB - We describe results of testing blood donors in London, UK, for severe acute respiratory disease coronavirus 2 (SARS-CoV-2) IgG before and after lockdown measures. Anonymized samples from donors 17-69 years of age were tested using 3 assays: Euroimmun IgG, Abbott IgG, and an immunoglobulin receptor-binding domain assay developed by Public Health England. Seroprevalence increased from 3.0% prelockdown (week 13, beginning March 23, 2020) to 10.4% during lockdown (weeks 15- 16) and 12.3% postlockdown (week 18) by the Abbott assay. Estimates were 2.9% prelockdown, 9.9% during lockdown, and 13.0% postlockdown by the Euroimmun assay and 3.5% prelockdown, 11.8% during lockdown, and 14.1% postlockdown by the receptor-binding domain assay. By early May 2020, nearly 1 in 7 donors had evidence of past SARS-CoV-2 infection. Combining results from the Abbott and Euroimmun assays increased seroprevalence by 1.6%, 2.3%, and 0.6% at the 3 timepoints compared with Euroimmun alone, demonstrating the value of using multiple assays.
UR - http://www.scopus.com/inward/record.url?scp=85108667471&partnerID=8YFLogxK
U2 - 10.3201/eid2707.203167
DO - 10.3201/eid2707.203167
M3 - Article
AN - SCOPUS:85108667471
SN - 1080-6040
VL - 27
SP - 1795
EP - 1801
JO - Emerging Infectious Diseases
JF - Emerging Infectious Diseases
IS - 7
ER -